Loading the state's markets…
Loading the state's markets…
Loading the market…
Medicare market size, surgeons and outlook to 2030
Medicare fee-for-service breast biopsy & localization cases in Connecticut: reported (2020, the pandemic year, left out of the line), then forecast with its 80% range. One year ahead, this procedure’s market forecast has been off by 3% on average (255 state-years, 2020–2024): a close guide.
| Year | Surgeons | Medicare FFS | Advantage share |
|---|---|---|---|
| 2019 | 50 | 3,389 | 46% |
| 2020 | 52 | 3,052 | 50% |
| 2021 | 56 |
Image-guided breast biopsy and marker/localization placement. Professional codes (what the surgeon bills): CPT 19081, 19083, 19085, 19281, 19283, 19285.
Surgeons and fee-for-service cases are from CMS’s Medicare Physician & Other Practitioners files, counted where the surgeon billed; state totals include the cases CMS leaves out of the surgeon-level file (under 11 patients). All Medicare adds patients in Medicare Advantage at the state’s enrollment share; all payers scales Medicare by its share of the procedure nationally. The forecast carries cases per resident 65+ forward with the Census projection of residents 65+. How the numbers are made · Data sources
The 10 busiest do 45% of the cases CMS names in Connecticut; 25 surgeons do 80% of them.
MedaRep names every one, ranked by volume, with their practice, hospitals, trend, forecast and which device companies already engage with them.
| State | Surgeons | Medicare FFS | Growth since 2019 | Per 1,000 | Out of hospital | Forecast |
|---|---|---|---|---|---|---|
| New York | 288 | 16,847+0.4%/yr | +0.4%/yr | 9.9 | 43% | 18,000 in 2030+1.1%/yr |
| Pennsylvania | 180 |
| Surgeons | Medicare FFS | Growth since 2019 | Per 1,000 | Out of hospital | Forecast | |
|---|---|---|---|---|---|---|
| Tumor & fibroid embolization | 3 | 119−5.9%/yr | −5.9%/yr | 0.40.6× | 0% | 170 in 2030+6.1%/yr |
Breast biopsy & localization in every state, and its device makers · Every procedure market in Connecticut · Every state · Compare with New York
| 2024 |
| 2,686 |
| 59% |
| 2025 est. | ≈ 2,660 | – |
| 2026 est. | ≈ 2,780 | – |
| 3,312 |
| 53% |
| 2022 | 49 | 3,054 | 54% |
| 2023 | 47 | 2,939 | 57% |
| 2024 | 40 | 2,686 | 59% |
| 2025 from claims | – | 2,659 2,440–2,813 | 63% |
| 2026 forecast | – | 2,782 2,448–3,211 | 62% |
| 2027 forecast | – | 2,779 2,376–3,312 | 63% |
| 2028 forecast | – | 2,774 2,315–3,397 | 64% |
| 2029 forecast | – | 2,768 2,261–3,472 | 65% |
| 2030 forecast | – | 2,761 2,212–3,538 | 65% |
In 2025, 77% hospital outpatient, 23% office.
| 9,684−1.2%/yr |
| −1.2%/yr |
| 7.6 |
| 8% |
| 10,100 in 2030+0.8%/yr |
| Massachusetts | 117 | 7,183−0.3%/yr | −0.3%/yr | 8.0 | 12% | 8,190 in 2030+2.2%/yr |
| New Jersey | 124 | 7,0630%/yr | 0%/yr | 7.1 | 39% | 8,480 in 2030+3.1%/yr |
| Rhode Island | 25 | 1,437+8.2%/yr | +8.2%/yr | 17.1 | 37% | 1,840 in 2030+4.2%/yr |
| New Hampshire | 20 | 1,151−0.9%/yr | −0.9%/yr | 5.3 | 19% | 1,410 in 2030+3.4%/yr |
| Maine | 16 | 918−3.4%/yr | −3.4%/yr | 6.3 | 0% | 1,010 in 2030+1.6%/yr |
| Vermont | 13 | 477−0.9%/yr | −0.9%/yr | 4.4 | 0% | 1,320 in 2030+18%/yr |
Share of the cases CMS names by surgeon, by where they billed. Open one for its ranking.
Exact Sciences leads with 76% of company spending on these surgeons in 2025, +25 pts on 2024.
In 2025, 16 companies reported engagement with Connecticut’s surgeons worth $70K in consulting, speaking, meals and travel tied to these products, about $1,753 per surgeon billing it. Royalties are left out.
FDA, last 12 months: 4 clearances and approvals in the category, 3 recalled product lines. A recall is a public FDA notice, not a finding of fault.
Which surgeons each company engages, and the dollars reported, are in the ranking. Open Payments shows the payments companies reported. It suggests engagement, not which devices a surgeon uses, and is not evidence of wrongdoing. Every company in the category.